Press Release: AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024
Carl Hansen Buys Handful Of Shares In AbCellera Biologics
AbCellera to Present at Upcoming Investor Conferences in September
AbCellera Biologics Inc. (ABCL): A Top Contender Among Canada's Best Penny Stocks in 2024
KeyBanc Maintains AbCellera Biologics(ABCL.US) With Buy Rating
KeyBanc analyst Scott Schoenhaus maintains $AbCellera Biologics(ABCL.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 36.7% and a total average return of -2.9%
KeyBanc Keeps Their Buy Rating on AbCellera Biologics (ABCL)